fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

Update on regulatory review of lecanemab for early Alzheimer’s disease by the European Commission – Eisai

Written by | 21 Apr 2025 | Neurology

Eisai Co., Ltd. and Biogen Inc. announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as a treatment for early AD (mild cognitive impairment and mild dementia due to Alzheimer’s disease (AD) by the European Commission (EC).

The final process for the EC decision on lecanemab’s Marketing Authorisation Application (MAA) is underway, following the reconfirmation of the positive opinion for lecanemab’s approval by the Committee for Medicinal Products for Human Use (CHMP) in February 2025. Following the EC deliberations on the MAA in its Standing Committee in March 2025, the Appeal Committee has conducted its deliberations and did not reach a decision.

In accordance with the legislation, the final decision regarding this MAA will be taken by the EC. Eisai will promptly disclose the final decision by the EC as soon as it is announced.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.